Combating animal cancers with advanced genetics.
Leading the way with the world’s first full-cycle precision veterinary oncology solution.
VetOncoPanel™
Pioneering genomic NGS Panel for canine and feline solid tumors, guiding targeted and immunotherapy based on human-relevant mutations.
VetOncoOrgan™
Personalized tumor organoid drug sensitivity screening to predict patient-specific treatment responses and guide precise therapy selection.
VetOncoTrace™
Personalized Minimal Residual Disease (MRD) Panel for feline & canine solid tumor based on tumor-specific fingerprints for early relapse detection and timely intervention.
Omics Service
We are delighted to share our multiomics capabilities to empower researchers with comprehensive insights across genomics, transcriptomics, epigenomics and radiomics.
We provide
Our Pipeline
Antibody Therapies
OcraBio is advancing a pipeline of antibody therapies targeting cancer and immune diseases in companion animals.
By leveraging our dedicated veterinary clinical trial center and AI-driven antibody discovery workflow, we dramatically shorten the feedback-to-iteration cycle across R&D, from early discovery to clinical validation. This infrastructure enables rapid in vivo proof-of-concept (PoC) studies and accelerates patient recruitment and enrollment for clinical trials.
To learn more, please refer to Our Pipeline.
Ocra Biotechnology Co., Limited
Unit 5-6, International Biomedical Industrial Park (Phase II), Shenzhen
